Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of being satiated, with the biopharma paying $25 million upfront to Arrowhead | Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steatohepatitis (MASH). Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers…

Will Maddox · 2026-05-06

Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steatohepatitis (MASH).

Source: FierceBiotech